RecruitingNot ApplicableNCT05914649

NC Testing in LC & POTS

Neurocognitive Testing in Long COVID and Postural Tachycardia Syndrome Patients With Normal Saline: A Pilot Study


Sponsor

University of Calgary

Enrollment

100 participants

Start Date

Sep 19, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Post-Acute Sequelae of COVID (PASC, or "Long COVID") experience cognitive dysfunction. The investigators will test the hypothesis that 999 mL of IV saline will improve cognitive function in patients with POTS and Long COVID compared to placebo (50 mL of saline).


Eligibility

Min Age: 18 YearsMax Age: 60 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying IV normal saline (50 mL infusion) and IV normal saline (999 mL infusion) for people with post-acute sequelae of sars-cov-2 infection and postural orthostatic tachycardia syndrome. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 60 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERIV normal saline (999 mL infusion)

999 mL of IV normal saline will be infused intravenously

OTHERIV normal saline (50 mL infusion)

50 mL of IV normal saline will be infused intravenously as a placebo control.


Locations(1)

University of Calgary

Calgary, Alberta, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05914649


Related Trials